Volume 36 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2020  >  36(3): 295-299
HEYu, XUHai-yan, SHANJin-jun, ZHAOXia, SHENCun-si, JIJian-jian, LINLi-li, YANGRui, XIETong, WANGShou-chuan. Network Pharmacology of Jinxin Oral Liquid in the Treatment of COVID-19[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(3): 295-299.
Citation: HEYu, XUHai-yan, SHANJin-jun, ZHAOXia, SHENCun-si, JIJian-jian, LINLi-li, YANGRui, XIETong, WANGShou-chuan. Network Pharmacology of Jinxin Oral Liquid in the Treatment of COVID-19[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(3): 295-299.
shu

Network Pharmacology of Jinxin Oral Liquid in the Treatment of COVID-19

  • 1.

    Jiangsu Key Laboratory for Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing, 210023, China

  • 2.

    Microbiological Laboratory, Nantong Center for Disease Control and Prevention, Nantong, 226007, China

  • Publish Date: 2020-05-10
    Abstract
  • OBJECTIVE The network pharmacology was used to explore the targets of Jinxin oral Liquid in the treatment of COVID-19. METHODS TCMSP database was used to mining the drug-like components in Jinxin oral Liquid and corresponding targets. The targets of pneumonia-related diseases in DisGeNET library was pointed and matched to the components' targets. STRING database was used for protein interaction network diagram. The DAVID website was used for further gene ontology analysis. RESULTS A total of 129 drug like compounds were obtained. Totally， 75 gene targets were matched to drug like components and pneumonia-related diseases. Protein interaction and gene ontology analysis suggested that the antiviral immune response and anti-inflammatory responses are most enriched. CONCLUSION The components in Jinxin oral Liquid were the possible candidates for treatment of COVID-19.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University[EB/OL]. （2020-04-02）[2020-04-02].https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
    [2]
    QIAN WJ， SHAN JJ， SHEN CS， et al. Brain metabolomics reveal the antipyretic effects of Jinxin Oral Liquid in young rats by using gas chromatography-mass spectrometry[J]. Metabolites， 2019， 9: 6-17.
    [3]
    DU LN， XIE T， XU JY， et al. A metabolomics approach to studying the effects of Jinxin oral liquid on RSV-infected mice using UPLC/LTQ-Orbitrap mass spectrometry[J]. J Ethnopharmacol， 2015，174(4):25-36.
    [4]
    周沁阳， 蔡文涛， 陈勇.中药抗流感病毒活性及作用机制研究新进展[J].中草药， 2019， 50(7):1719-1726.
    [5]
    姚卫峰，翟园园，林丽丽，等.融合“成分-靶点-共有通路”网络和分子对接技术的清肺口服液抗新型冠状病毒肺炎的活性成分初探[J].南京中医药大学学报，2020，36（2）：174-178.
    [6]
    刘志强， 王博龙. 中药网络药理学药效成分筛选与靶标预测的研究进展[J].中成药， 2019， 41(1):171-178.
    [7]
    解静， 高杉， 李琳， 等. 网络药理学在中药领域中的研究进展与应用策略[J].中草药， 2019， 50(10):2257-2265.
    [8]
    LU RJ， ZHAO X， LI J， et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding[J]. Lancet， 2020， 395(10224):565-574.
    [9]
    杜宏波， 张耀圣， 王彤， 等.肝脾辨治在新型冠状病毒肺炎诊治中的思考[J]. 世界中医药，2020， 2(8):1-7.
    [10]
    张侠， 李柳， 戴广川，等. 南京地区42例新型冠状病毒肺炎临床特征与中医证候初探[J].南京中医药大学学报， 2020，36(2):145-148.
    [11]
    KARABIN M， HUDCOVA T， JELINEK L， et al. Biotransformations and biological activities of hop flavonoids[J]. Biotechnol Adv， 2015， 33(6): 1063-1090.
    [12]
    TAKUMI K， TARO K. Toll-like receptor signaling pathways[J]. Front Immunol， 2014， 5(461):461-469.
    [13]
    何玉洁， 潘建平. 病原菌对NOD样受体及Toll样受体信号通路介导的固有免疫逃逸机制研究进展[J]. 浙江大学学报(医学版)， 2017， 46(2):218-224.
    [14]
    RUCKWARDT TJ， MORABITO KM， GRAHAM BS. Immunological lessons from respiratory syncytial virus vaccine development[J]. Immunity， 2019， 51(3):429-442.
    [15]
    LAMBERT L， SAGFORS AM， OPEBSHAW PJM， et al. Immunity to RSV in Early-Life[J]. Front Immunol， 2014， 5(466):1-14.
    [16]
    LIU Q， ZHOU YH， YANG ZQ， et al. The cytokine storm of severe influenza and development of immunomodulatory therapy[J]. Cell Mol Immunol， 2016， 13(1):3-10.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (538) PDF downloads(391) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return